DOCSLIB.ORG

Superparamagnetic Iron Oxide Nanoparticles in Biomedicine

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Superparamagnetic Iron Oxide Nanoparticles in Biomedicine Übersicht 1149 Superparamagnetic Iron Oxide Nanoparticles in Biomedicine: Applications and Developments in Diagnostics and Therapy Superparamagnetische Eisenoxid-Nanopartikel in der Biomedizin: Anwendungen und Entwicklungen in Diagnostik und Therapie Authors H. Ittrich, K. Peldschus, N. Raabe, M. Kaul, G. Adam Affiliation Diagnostic and Interventional Radiology Department and Clinic, Center für Radiology and Endoscopy, University Medical Center Hamburg-Eppendorf Key words Abstract Key Points: " ● SPIO ! ▶ SPIO can be used for diagnosis, MR ima- ●" molecular imaging Superparamagnetic iron oxide nanoparticles ging, and treatment. ●" MRI (SPIO) can be used to image physiological pro- ▶ Monodisperse SPIO improve physicochem- ●" contrast media cesses and anatomical, cellular and molecular istry and pharmacodynamics. ●" iron oxide ●" nanoparticles changes in diseases. The clinical applications ▶ SPIO in targeted probes can be used in in- range from the imaging of tumors and metas- vitro diagnostic imaging (μNMR). tases in the liver, spleen and bone marrow, ▶ The potential to use SPIO in magnetic par- the imaging of lymph nodes and the CNS, ticle imaging (MPI) must be evaluated. MRA and perfusion imaging to atherosclero- Citation Format: tic plaque and thrombosis imaging. New ex- ▶ Ittrich H, Peldschus K, Raabe N et al. Super- perimental approaches in molecular imaging paramagnetic Iron Oxide Nanoparticles in describe undirected SPIO trapping (passive Biomedicine: Applications and Develop- targeting) in inflammation, tumors and asso- ments in Diagnostics and Therapy. Fortschr ciated macrophages as well as the directed Röntgenstr 2013; 185: 1149–1166 accumulation of SPIO ligands (active target- ing) in tumor endothelia and tumor cells, areas of apoptosis, infarction, inflammation and degeneration in cardiovascular and neu- Zusammenfassung rological diseases, in atherosclerotic plaques ! or thrombi. The labeling of stem or immune Mithilfe von Superparamagnetischen Eisenoxid- eingereicht 25.10.2012 akzeptiert 18.3.2013 cells allows the visualization of cell therapies Nanopartikeln (SPIO) können physiologische Ab- or transplant rejections. The coupling of SPIO läufe sowie anatomische, zelluläre und molekulare Bibliography to ligands, radio- and/or chemotherapeutics, Veränderungen in Krankheitsprozessen abgebildet DOI http://dx.doi.org/ embedding in carrier systems or activatable werden. Die klinischen Anwendungen reichen von 10.1055/s-0033-1335438 smart sensor probes and their externally con- der Tumor- und Metastasenbildgebung in Leber, Published online: 5.9.2013 This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited. Fortschr Röntgenstr 2013; 185: trolled focusing (physical targeting) enable Milz und Knochenmark, über die Lymphknoten- 1149–1166 © Georg Thieme molecular tumor therapies or the imaging of und ZNS-Bildgebung, die MR-Angiografie und Per- Verlag KG Stuttgart · New York · metabolic and enzymatic processes. Mono- fusionsdiagnostik bis hin zur atherosklerotischen ISSN 1438-9029 disperse SPIO with defined physicochemical Plaque- und Thrombosebildgebung. Die experi- and pharmacodynamic properties may im- mentellen Anwendungsfelder in der Molekularen prove SPIO-based MRI in the future and as Bildgebung umfassen neben ungerichteter SPIO- Correspondence Dr. Harald Ittrich targeted probes in diagnostic magnetic reso- Anreicherung (Passive Targeting) in Entzündungs- Diagnostic and Interventional nance (DMR) using chip-based μNMR may regionen und Tumoren sowie assoziierten Makro- Radiology Department and significantly expand the spectrum of in vitro phagen die zielgerichtete Akkumulation von SPIO- Clinic, Center für Radiology and analysis methods for biomarker, pathogens Liganden (Active Targeting) an/in Tumorendothe- Endoscopy, University Medical and tumor cells. Magnetic particle imaging lien und Tumorzellen, Apoptose-, Infarkt-, Inflam- Center Hamburg-Eppendorf (MPI) as a new imaging modality offers new mations- und Degenerationsarealen in kardio- Martinistraße 52 applications for SPIO in cardiovascular, onco- vaskulären und neurologischen Erkrankungen, in 20246 Hamburg Tel.: ++ 49/40/4 28 03 31 16 logical, cellular and molecular diagnostics atherosklerotischen Plaques oder Thromben. Die Fax: ++ 49/40/4 28 03 67 99 and therapy. SPIO-Markierung von Stamm- oder Immunzellen [email protected] erlaubt die Visualisierung von Zelltherapien oder Ittrich H et al. Superparamagnetic Iron Oxide… Fortschr Röntgenstr 2013; 185: 1149–1166 1150 Übersicht Transplantat-Abstoßungen. Die Kopplung von SPIO an Liganden, field of molecular imaging describe on a cellular level the Radio- und/oder Chemotherapeutika, die Einbettung in Trägersys- in vitro labeling of cell types (e. g. macrophages, lympho- teme oder aktivierbare Sonden sowie deren extern gesteuerter Fo- cytes, progenitor/stem cells) with SPIO (cell labeling) and kussierung (Physical Targeting) ermöglicht molekulare Tumorther- their diagnostic in vivo MR imaging and migration tracking apien sowie die Abbildung metabolischer und enzymatischer (tracking/migration monitoring) [20, 21]. Additional studies Prozesse. Monodisperse SPIO mit definierten physikochemischen on a molecular level describe the use of SPIO and specifical- und pharmakodynamischen Eigenschaften könnten die SPIO-un- ly targeted SPIO conjugates (targeted probes) for labeling terstützte MRT verbessern und zukünftig als zielgerichtete Sonden cell-surface molecules (e. g. cell receptors or antigens [22]) in der Diagnostischen Magnetresonanz (DMR) unter Nutzung von in combination with gene therapy, chemotherapeutic, or chipbasierten μNMR das Spektrum der In-vitro-Analysemethoden radiotherapeutic agents as a combined diagnostic-thera- für Biomarker, Pathogene und Tumorzellen entscheidend erwei- peutic agent (theranostics [23]) and tumor-thermoablative tern. Magnetic Particle Imaging (MPI) als neues Abbildungsverfah- use in hyperthermia [24]. The embedding of SPIO in na- ren könnte SPIO sowohl in der kardiovaskulären, onkologischen, noencapsulations or microencapsulations with different zellulären und molekularen Diagnostik und Therapie neue Anwen- controllable surface properties (e. g. in micelles or lipo- dungsfelder eröffnen. somes) recently made it possible to use SPIO in the imaging of metabolic processes (e. g. lipid metabolism [25, 26]). Moreover, the synthesis of novel, monodisperse SPIO with Introduction optimized physicochemical and pharmacodynamic proper- ! ties allows more precise addressing of target structures, The term superparamagnetic, first mentioned in the mid- greater accumulation in the target area, improved target- 1950 s [1], describes the ability of a ferrimagnetic or ferro- environment contrast, and more exact parametric or quan- magnetic material to be magnetized in the presence of an titative SPIO-MRI. external magnetic field and to completely lose this magne- In addition to the use of SPIO in diagnostic MRI and in the tization once the magnetic field is deactivated (no rema- treatment of diverse diseases, use in a new tomographic nent magnetization) [2]. This phenomenon is physically imaging modality currently undergoing preclinical evalua- based on the Brown and Neel relaxation [3]. tion, namely magnetic particle imaging (MPI) [27], is being Nanoparticles typically refer to particles with a size of tested and optimized. 1 – 100 nm, but the physical, chemical, and biological prop- Based on the statements of Taupitz et al. [28], the present erties can differ greatly compared to macroscopic material study is intended to provide a current overview of the mor- with the same composition [4]. phological, physical-chemical, and biological characteristics Superparamagnetic particles of iron oxide (SPIO) have an of different SPIO, the current status in clinical application, iron oxide core that is monomer- or polymer-coated/stabi- and the current and future preclinical experimental appli- lized. The advantages of SPIO, such as good suspensibility, a cation fields of SPIO in molecular imaging and treatment. highly reactive surface, uniform particle size distribution, and the possibility of additional coating modification by conjugating with specifically binding ligands (e. g. antibo- Particle types and particle properties dies) has made it possible to use these particles in biomedi- ! cine since the mid-1970 s in immunomagnetic cell separa- Definition and magnetic properties in MRI tion [5]. Superparamagnetic particles of iron oxide (SPIO) are a se- With the broad application of magnetic resonance imaging parate class of MR contrast agents that have a size spectrum (MRI) in medical diagnostics starting in the mid-1980 s, an- of only a few nanometers to several micrometers and influ- other SPIO application field developed, namely use as a neg- ence the spin-spin (T2) and spin-lattice (T1) relaxation. ative, i. e. signal-eliminating, contrast agent in MRI [6]. The After local accumulation, SPIO shorten the T2, T2* or T1 re- nonspecific uptake of SPIO in the mononuclear phagocyte laxation times of surrounding tissues. This causes a signal- system (MPS) or reticuloendothelial system (RES) after in- reducing T2 and T2* effect (negative contrast) or a signal-in- travenous application made it possible at the end of the creasing T1 effect (positive contrast). In general, the r2 or r2* 1980 s to use SPIO in preclinical and clinical diagnostic MRI relaxivity of SPIO as the reciprocal of the T2 or T2* relaxa- This document was downloaded for personal use only. Unauthorized
Load more

Recommended publications
  • List of Union Reference Dates A
    Active substance name (INN) EU DLP BfArM / BAH DLP yearly PSUR 6-month-PSUR yearly PSUR bis DLP (List of Union PSUR Submission Reference Dates and Frequency (List of Union Frequency of Reference Dates and submission of Periodic Frequency of submission of Safety Update Reports, Periodic Safety Update 30 Nov. 2012) Reports, 30 Nov.
    [Show full text]
  • ++449Guide to Radiology Procedures.Pdf
    For Alexander and Olivia For Elsevier Content Strategist: Jeremy Bowes Content Development Specialist: Helen Leng Project Manager: Julie Taylor Designer/Design Direction: Miles Hitchen Illustration Manager: Jennifer Rose Illustrator: David Gardner and Antbits Ltd CHAPMAN AND NAKIELNY’S GUIDE TO RADIOLOGICAL PROCEDURES Edited by Nick Watson MBChB MRCP FRCR Consultant Radiologist, University Hospital of North Staffordshire, Stoke-on-Trent; Senior Lecturer, Keele University Medical School, Keele, UK SIXTH EDITION Edinburgh • London • New York • Oxford • Philadelphia • St Louis • Sydney • Toronto 2014 © 2014 Elsevier Ltd. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval system, without permission in writing from the publisher. Details on how to seek permission, further information about the publisher’s permissions policies and our arrangements with organizations such as the Copyright Clearance Center and the Copyright Licensing Agency, can be found at our website: www.elsevier.com/permissions. This book and the individual contributions contained in it are protected under copyright by the publisher (other than as may be noted herein). First edition 1981 Second edition 1986 Third edition 1993 Fourth edition 2001 Fifth edition 2009 Sixth edition 2014 ISBN 9780702051814 Ebook ISBN: 9780702054792 British Library Cataloguing in Publication Data A catalogue record for this book is available from the British Library Library of Congress Cataloging in Publication Data A catalog record for this book is available from the Library of Congress Notices Knowledge and best practice in this field are constantly changing. As new research and experience broaden our understanding, changes in research methods, professional practices, or medical treatment may become necessary.
    [Show full text]
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1
    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
    [Show full text]
  • Page 1 Note: Within Nine Months from the Publication of the Mention
    Europäisches Patentamt (19) European Patent Office & Office européen des brevets (11) EP 1 411 992 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 49/04 (2006.01) A61K 49/18 (2006.01) 13.12.2006 Bulletin 2006/50 (86) International application number: (21) Application number: 02758379.8 PCT/EP2002/008183 (22) Date of filing: 23.07.2002 (87) International publication number: WO 2003/013616 (20.02.2003 Gazette 2003/08) (54) IONIC AND NON-IONIC RADIOGRAPHIC CONTRAST AGENTS FOR USE IN COMBINED X-RAY AND NUCLEAR MAGNETIC RESONANCE DIAGNOSTICS IONISCHES UND NICHT-IONISCHES RADIOGRAPHISCHES KONTRASTMITTEL ZUR VERWENDUNG IN DER KOMBINIERTEN ROENTGEN- UND KERNSPINTOMOGRAPHIEDIAGNOSTIK SUBSTANCES IONIQUES ET NON-IONIQUES DE CONTRASTE RADIOGRAPHIQUE UTILISEES POUR ETABLIR DES DIAGNOSTICS FAISANT APPEL AUX RAYONS X ET A L’IMAGERIE PAR RESONANCE MAGNETIQUE (84) Designated Contracting States: (74) Representative: Minoja, Fabrizio AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Bianchetti Bracco Minoja S.r.l. IE IT LI LU MC NL PT SE SK TR Via Plinio, 63 20129 Milano (IT) (30) Priority: 03.08.2001 IT MI20011706 (56) References cited: (43) Date of publication of application: EP-A- 0 759 785 WO-A-00/75141 28.04.2004 Bulletin 2004/18 US-A- 5 648 536 (73) Proprietor: BRACCO IMAGING S.p.A. • K HERGAN, W. DORINGER, M. LÄNGLE W.OSER: 20134 Milano (IT) "Effects of iodinated contrast agents in MR imaging" EUROPEAN JOURNAL OF (72) Inventors: RADIOLOGY, vol. 21, 1995, pages 11-17, • AIME, Silvio XP002227102 20134 Milano (IT) • K.M.
    [Show full text]
  • Magnetic Resonance Imaging (MRI) Contrast Agents Frequently Asked Questions
    Magnetic Resonance Imaging (MRI) Contrast Agents Frequently Asked Questions 1. What is an MRI contrast agent? MRI contrast agents are chemical substances that contain the metal gadolinium. They are injected through a vein for many magnetic resonance imaging (MRI) scans. 2. What are the benefits of MRI contrast agents? When injected through a vein into the body, MRI contrast agents improve how internal organs, blood vessels, and other tissues look on the MRI images. This helps detect problems and diagnose medical conditions. For many medical conditions, the use of MRI contrast agents is a necessary part of the MRI. 3. What are the risks from MRI contrast agents? A. Injection problems. Any injection can cause injury to a nerve, artery, or vein, or result in infection. The contrast agent can also sometimes leak outside of the vein into the soft tissues during injection. This is called extravasation and is uncommon (about 1 in every 1,000 injections). This may be painful, but the pain is generally relieved by cold or warm compresses. B. Allergic reaction. Some people can be allergic to MRI contrast agents. There can sometimes be a mild reaction to the contrast agent such as itching and hives (about 1 in every 100 injections). Uncommonly, there can be a serious reaction to the contrast agent such as changes in blood pressure, cardiac distress, and respiratory distress (about 1 in every 10,000 injections). Very rarely this can result in death. For patients who have had a previous mild allergic reaction to an MRI contrast agent and need another MRI with MRI contrast agent, it is generally safe to do so after taking anti-allergy medications.
    [Show full text]
  • 207/2015 3 Lääkeluettelon Aineet, Liite 1. Ämnena I Läkemedelsförteckningen, Bilaga 1
    207/2015 3 LÄÄKELUETTELON AINEET, LIITE 1. ÄMNENA I LÄKEMEDELSFÖRTECKNINGEN, BILAGA 1. Latinankielinen nimi, Suomenkielinen nimi, Ruotsinkielinen nimi, Englanninkielinen nimi, Latinskt namn Finskt namn Svenskt namn Engelskt namn (N)-Hydroxy- (N)-Hydroksietyyli- (N)-Hydroxietyl- (N)-Hydroxyethyl- aethylprometazinum prometatsiini prometazin promethazine 2,4-Dichlorbenzyl- 2,4-Diklooribentsyyli- 2,4-Diklorbensylalkohol 2,4-Dichlorobenzyl alcoholum alkoholi alcohol 2-Isopropoxyphenyl-N- 2-Isopropoksifenyyli-N- 2-Isopropoxifenyl-N- 2-Isopropoxyphenyl-N- methylcarbamas metyylikarbamaatti metylkarbamat methylcarbamate 4-Dimethyl- ami- 4-Dimetyyliaminofenoli 4-Dimetylaminofenol 4-Dimethylaminophenol nophenolum Abacavirum Abakaviiri Abakavir Abacavir Abarelixum Abareliksi Abarelix Abarelix Abataceptum Abatasepti Abatacept Abatacept Abciximabum Absiksimabi Absiximab Abciximab Abirateronum Abirateroni Abirateron Abiraterone Acamprosatum Akamprosaatti Acamprosat Acamprosate Acarbosum Akarboosi Akarbos Acarbose Acebutololum Asebutololi Acebutolol Acebutolol Aceclofenacum Aseklofenaakki Aceklofenak Aceclofenac Acediasulfonum natricum Asediasulfoni natrium Acediasulfon natrium Acediasulfone sodium Acenocoumarolum Asenokumaroli Acenokumarol Acenocumarol Acepromazinum Asepromatsiini Acepromazin Acepromazine Acetarsolum Asetarsoli Acetarsol Acetarsol Acetazolamidum Asetatsoliamidi Acetazolamid Acetazolamide Acetohexamidum Asetoheksamidi Acetohexamid Acetohexamide Acetophenazinum Asetofenatsiini Acetofenazin Acetophenazine Acetphenolisatinum Asetofenoli-isatiini
    [Show full text]
  • Physician Services Fee Schedule
    REPORT: RS04328‐R1328 NORTH CAROLINA DEPARTMENT OF HEALTH AND HUMAN SERVICES PHYSICIAN FEE SCHEDULE AS OF: 05/11/2017 Physician Fee Schedule Provider Specialty 001 Effective Date: 1/1/2018 The inclusion of a rate on this table does not guarantee that a service is covered. Please refer to the Medicaid Billing Guide and the Medicaid and Health Choice Clinical Policies on the DMA Web Site. Providers should always bill their usual and customary charges. Please use the monthly NC Medicaid Bulletins for additions, changes and deletion to this schedule. Medicaid Maximum Allowable NON- FACILITY FACILITY PROCEDURE CODE MODIFIER PROCEDURE DESCRIPTION RATE RATE EFFECTIVE DATE 01967 NEURAXIAL LABOR ANALGESIA/ANESTHESIA FOR $ 209.63 $ 209.63 01996 DAILY HOSPITAL MANAGEMENT OF EPIDURAL OR $ 38.93 $ 38.93 10021 FINE NEEDLE ASPIRATION; WITHOUT IMAGING $ 52.36 $ 100.48 10022 FINE NEEDLE ASPIRATION; WITH IMAGING GUI $ 51.97 $ 103.17 10030 GUIDE CATHET FLUID DRAINAGE $ 126.07 $ 615.23 10035 PERQ DEV SOFT TISS 1ST IMAG $ 74.46 $ 437.80 10036 PERQ DEV SOFT TISS ADD IMAG $ 37.49 $ 379.35 10040 ACNE SURGERY $ 63.53 $ 72.20 10060 DRAINAGE OF ABSCESS $ 67.39 $ 77.74 10061 DRAINAGE OF ABSCESS $ 120.14 $ 133.85 10080 DRAINAGE OF PILONIDAL CYST $ 68.87 $ 114.75 10081 DRAINAGE OF PILONIDAL CYST $ 120.71 $ 181.14 10120 FOREIGN BODY REMOVAL, SKIN $ 66.08 $ 94.90 10121 FOREIGN BODY REMOVAL, SKIN $ 135.29 $ 185.09 10140 DRAINAGE OF BLOOD EFFUSION $ 86.33 $ 109.27 10160 PUNCTURE DRAINAGE OF LESION $ 69.52 $ 88.81 10180 INCISION AND DRAINAGE, COMPLEX $ 127.40 $ 164.05
    [Show full text]
  • Sonovue® – Liver Dynamic Contrast Enhancement in Real Time
    Bracco. The contrast imaging specialists. SonoVue® – Liver Dynamic Contrast Enhancement in Real Time BRACCO IMAGING Welcome to Bracco Imaging Bracco Imaging S.p.A., part of the Bracco Group, is one of the world’s leading companies in the diagnostic imaging business. Headquartered in Milan, Italy, Bracco Imaging develops, manufactures and markets diagnostic imaging agents and solutions that meet medical needs. Bracco Imaging offers a product and solution portfolio for all key diagnostic imaging modalities: X-Ray Imaging (including Computed Tomography-CT, Interventional Radiology, and Cardiac Catheterization), Magnetic Resonance Imaging (MRI), Contrast Enhanced Ultrasound (CEUS), Nuclear Medicine through radioactive tracers, and Gastrointestinal Endoscopy. The diagnostic imaging offer is completed by several medical devices and advanced administration systems for contrast imaging products in the fields of radiology and cardiology. These include the Empower line of contrast injection systems for CT and MRI procedures, the syringe-less contrast administration system CT Exprés and VueJect, our ultrasound contrast agents’ infusion pump. The Company operates in over 90 markets worldwide, either directly or indirectly, through subsidiaries, joint ventures, licenses and distribution partnership agreements. With an on-going research covering all key modalities, Bracco Imaging has a strong presence in key geographies: North America; Europe and Japan operating through the Joint Venture Bracco-Eisai Co., Ltd. The Company also operates in Brazil, South Korea, and China through the Joint Venture Bracco Sine Pharmaceutical Corp. Ltd. Operational investments have been made in order to achieve top quality and compliance with a sustainable eco-friendly production. Manufacturing activities are located in Italy, Switzerland, Japan, China and Germany.
    [Show full text]
  • Gadolinium Based Contrast Agents
    CE Credits Available CONSIDERATIONS IN THE SELECTION OF A NEW GADOLINIUM-BASED CONTRAST AGENT SUPPLEMENT TO MAY 2014 THE JOURNAL OF PRACTICAL MEDICAL IMAGING AND MANAGEMENT Considerations in the Selection of a New Gadolinium-Based Contrast Agent Michael F. Tweedle, PhD Emanuel Kanal, MD, FACR, FISMRM Robert Muller, PhD Stefanie Spielman Professor of Radiology Professor of Radiology and Neuroradiology Department of General, Organic & The Ohio State University University of Pittsburgh Medical Center Biochemical Chemistry Columbus, OH Pittsburgh, PA University of Mons Mons, Belgium Supported by an unrestricted educational grant from © May 2014 www.appliedradiology.com SUPPLEMENT TO APPLIED RADIOLOGY n 1 Publisher Kieran Anderson Executive Editor Cristen Bolan Art and Production Barbara A. Shopiro Applied Radiology and this supplement, Considerations in the Selection of a New Gadolinium-Based Contrast Agent, are published by Anderson Publishing, Ltd. The journal does not warrant the expertise of any author in a particular field, nor is it responsible for any statements by such authors. The opinions expressed in this supplement are those of the authors. They do not imply endorsement of advertised products and do not necessarily reflect the opinions or recommendations of our sponsors or the editors and staff of Applied Radiology. Copyright © 2014 by Anderson Publishing, Ltd., 180 Glenside Avenue, Scotch Plains, NJ 07076 All rights reserved. Cover images courtesy of Howard A. Rowley, MD. Considerations in the Selection of a New Gadolinium-Based Contrast Agent Our 3 esteemed faculty summarize the similarities and differences among the gadolinium-based contrast agents (GBCAs) currently utilized for magnetic resonance imaging (MRI), with emphasis on stability and relaxivity.
    [Show full text]
  • DISSERTATION INVESTIGATION of CATIONIC CONTRAST-ENHANCED COMPUTED TOMOGRAPHY for the EVALUATION of EQUINE ARTICULAR CARTILAGE Su
    DISSERTATION INVESTIGATION OF CATIONIC CONTRAST-ENHANCED COMPUTED TOMOGRAPHY FOR THE EVALUATION OF EQUINE ARTICULAR CARTILAGE Submitted by Bradley B. Nelson Department of Clinical Sciences In partial fulfillment of the requirements For the Degree of Doctor of Philosophy Colorado State University Fort Collins, Colorado Fall 2017 Doctoral Committee: Advisor: Christopher E. Kawcak Co-Advisor: Laurie R. Goodrich C. Wayne McIlwraith Mark W. Grinstaff Myra F. Barrett Copyright by Bradley Bernard Nelson 2017 All Rights Reserved ABSTRACT INVESTIGATION OF CATIONIC CONTRAST-ENHANCED COMPUTED TOMOGRAPHY FOR THE EVALUATION OF EQUINE ARTICULAR CARTILAGE Osteoarthritis and articular cartilage injury are substantial problems in horses causing joint pain, lameness and decreased athleticism resonant of the afflictions that occur in humans. This debilitating joint disease causes progressive articular cartilage degeneration and coupled with a poor capacity to heal necessitates that articular cartilage injury is detected early before irreparable damage ensues. The use of diagnostic imaging is critical to identify and characterize articular cartilage injury, though currently available methods are unable to identify these early degenerative changes. Cationic contrast-enhanced computed tomography (CECT) uses a cationic contrast media (CA4+) to detect the early molecular changes that occur in the extracellular matrix. Glycosaminoglycans (GAGs) within the extracellular matrix are important for the providing the compressive stiffness of articular cartilage and their degradation is an early event in the development of osteoarthritis. Cationic CECT imaging capitalizes on the electrostatic attraction between CA4+ and GAGs; exposing the proportional relationship between the amount of GAGs present within and the amount of CA4+ that diffuses into the tissue. The amount of CA4+ that resides in the tissue is then quantified through CECT imaging and estimates tissue integrity through nondestructive assessment.
    [Show full text]
  • Advisory Committee Briefing Document Medical Imaging Drugs Advisory Committee (MIDAC) September 8, 2017
    Dotarem® (gadoterate meglumine) Injection – NDA# 204781 Advisory Committee Optimark® (gadoversetamide) Injection - NDAs# 020937, 020975 & 020976 Briefing Document Advisory Committee Briefing Document Medical Imaging Drugs Advisory Committee (MIDAC) September 8, 2017 DOTAREM® (gadoterate meglumine) Injection NDA 204781 Guerbet LLC, 821 Alexander Rd, Princeton, NJ 08540 OPTIMARK® (gadoversetamide) Injection NDAs 020937, 020975 & 020976 Liebel-Flarsheim Company LLC, 1034 Brentwood Blvd., Richmond Heights, MO 63117 ADVISORY COMMITTEE BRIEFING MATERIALS AVAILABLE FOR PUBLIC RELEASE Information provided within this briefing document is based upon medical and scientific information available to date. ADVISORY COMMITTEE BRIEFING MATERIALS AVAILABLE FOR PUBLIC RELEASE Page 1 / 168 Dotarem® (gadoterate meglumine) Injection – NDA# 204781 Advisory Committee Optimark® (gadoversetamide) Injection - NDAs# 020937, 020975 & 020976 Briefing Document EXECUTIVE SUMMARY Gadolinium-based contrast agents (GdCAs) are essential for use in magnetic resonance imaging (MRI). Although non-contrast-enhanced MRI may be sufficient for use in some clinical conditions, contrast-enhanced MRI (CE-MRI) using GdCA provides additional vital diagnostic information in a number of diseases. It is widely recognized that CE-MRI increases diagnostic accuracy and confidence, and thus can impact the medical and/or surgical management of patients. Based on the chemical structure of the complexing ligand, GdCA are classified as linear (L-GdCA) or macrocyclic (M-GdCA) and can be ionic or nonionic and those characteristics have a dramatic influence on the stability of the GdCA. Dotarem®, a M-GdCA, was first approved in France in 1989. US-FDA approval was obtained in March 2013 for “intravenous use with MRI of the brain (intracranial), spine and associated tissues in adult and pediatric patients (2 years of age and older) to detect and visualize areas with disruption of the blood brain barrier (BBB) and/or abnormal vascularity”, at the dose of 0.1 mmol/kg BW.
    [Show full text]
  • PRESCRIBING INFORMATION CLARISCAN™ – Gadoteric Acid Please Refer to Full National Summary of Product Characteristics (Smpc) Before Prescribing
    PRESCRIBING INFORMATION CLARISCAN™ – gadoteric acid Please refer to full national Summary of Product Characteristics (SmPC) before prescribing. Further information available on request. PRESENTATION Clariscan 0.5 mmol/mL solution for injection. Solution for injection containing 279.3 mg/ml gadoteric acid (as gadoterate meglumine) equivalent to 0.5 mmol/mL. INDICATIONS For diagnostic use only. Clariscan should be used only when diagnostic information is essential and not available with unenhanced magnetic resonance imaging (MRI). Contrast agent for contrast enhancement in MRI for a better visualisation/delineation. Adult and paediatric population (0-18 years): lesions of the brain, spine, and surrounding tissues. Adults and children over 6 months Whole body MRI. Non-coronary angiography in adults only. DOSAGE AND METHOD OF ADMINISTRATION This medicinal product should only be administered by trained healthcare professionals with technical expertise in performing and interpreting gadolinium enhanced MRI. The lowest dose that provides sufficient enhancement for diagnostic purposes should be used. The dose should be calculated based on the patient’s body weight, and should not exceed the recommended dose per kilogram of body weight detailed in this section. MRI of brain and spine: Adults: The recommended dose is 0.1 mmol/kg BW, i.e. 0.2 mL/kg BW. In patients with brain tumours, an additional dose of 0.2 mmol/kg BW, i.e. 0.4 mL/kg BW, may improve tumor characterisation and facilitate therapeutic decision making. Children (0-18 years): The recommended and maximum dose of Clariscan is 0.1 mmol/kg body weight. Do not use more than one dose during a scan.
    [Show full text]